III

Jonathan Milner issues Open Letter to shareholders of Abcam plc

Retrieved on: 
Tuesday, October 10, 2023
MAKE, ACT, III, AWARE, NO, AMERICA, NOT, PAST, TIME, DATE, THIS, AS, NORTH, USE, ANY, OF, IT, FOR, UPON, FINANCIAL, FCA, ITS, SET, IS, TAX, EXPRESS, EUROPEAN UNION, ALL, FAIR, UPDATE, BY, FUTURE, EACH, AND, Glass fiber, Medical device, Audit, EU

T: +44 7733 265 198 / E: [email protected]

Key Points: 
  • T: +44 7733 265 198 / E: [email protected]
    T: +44 (0)20 3709 5700 / E: [email protected]
    T: +1 646 677 1811 / E: [email protected]
    THIS DOCUMENT HAS BEEN ISSUED BY DR. JONATHAN MILNER ("DR. MILNER").
  • DR. MILNER STRONGLY ADVISES ALL SHAREHOLDERS OF THE COMPANY TO READ THE PROXY STATEMENT AND OTHER PROXY MATERIALS AS THEY BECOME AVAILABLE BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION.
  • THE VIEWS EXPRESSED HEREIN REPRESENT THE OPINIONS OF DR. MILNER AS OF THE DATE HEREOF.
  • DR. MILNER HAS NOT SOUGHT OR OBTAINED CONSENT FROM ANY THIRD PARTY TO USE ANY STATEMENTS OR INFORMATION CONTAINED HEREIN.

Saratoga Investment Corp. Announces Fiscal Second Quarter 2024 Financial Results

Retrieved on: 
Monday, October 9, 2023
III, Investment, ATM, Share repurchase, Accounts payable, IRR, Depreciation, Quarter, NII, SBIC, Bank statement, CLO, EBITDA, BDC, Lisp (programming language), Securities and Exchange Commission (Nigeria), Ladenburg Thalmann, Tax, Webcast, AUM, Environment, Growth, Financial result, Grace note, SBA, JV, NAV, Earnings before interest, taxes, depreciation and amortization, Security (finance), Sale, Bank, Cryptocurrency, Real estate, Holding company, Q2

Since Saratoga Investment took over the management of the BDC, $907.7 million of repayments and sales of investments originated by Saratoga Investment have generated a gross unlevered IRR of 15.6%.

Key Points: 
  • Since Saratoga Investment took over the management of the BDC, $907.7 million of repayments and sales of investments originated by Saratoga Investment have generated a gross unlevered IRR of 15.6%.
  • Total expenses for the second fiscal quarter 2024, excluding interest and debt financing expenses, base management fees and incentive fees and income and excise taxes, decreased from $2.3 million to $2.1 million as compared to the first fiscal quarter 2024, and increased from $1.6 million from the last quarter ended August 31, 2022.
  • Net investment income yield as a percentage of average net asset value (“Net Investment Income Yield”) was 16.0% for the quarter ended August 31, 2023.
  • The Company previously declared in fiscal 2024 a quarterly dividend of $0.70 per share for the quarter ended May 31, 2023.

Cytokinetics Presents Baseline Characteristics From SEQUOIA-HCM at the HCM Society Scientific Sessions

Retrieved on: 
Friday, October 6, 2023
III, Research and development, Guideline, Calcium channel, Female, Disopyramide, VO2, N-terminal prohormone of brain natriuretic peptide, Obstruction, SD, LVEF, NYHA, Safety, Exercise, Patient, SAN, Cytokinetics, Medical Center, LVOT, Lahey Hospital & Medical Center, Pharmaceutical industry, HCM

SEQUOIA-HCM enrolled a total of 282 patients, with one third from the United States, one half from Europe and Israel, and the remainder from China.

Key Points: 
  • SEQUOIA-HCM enrolled a total of 282 patients, with one third from the United States, one half from Europe and Israel, and the remainder from China.
  • Background medical therapy consisted of beta-blockers (61%), calcium channel blockers (26.6%), and disopyramide (12.8%); combination background therapy was permitted.
  • At baseline, 75.9% of patients were NYHA functional class II, 23.8% were functional class III, and 0.4% were functional class IV.
  • Key baseline characteristics that remain blinded include left ventricular ejection fraction (LVEF), resting and Valsalva LVOT-G, and NT-proBNP.

Tenaya Therapeutics Doses First Patient in the MyPeak-1™ Phase 1b Clinical Trial of TN-201 for the Treatment of MYBPC3-Associated Hypertrophic Cardiomyopathy

Retrieved on: 
Thursday, October 5, 2023
III, Partnership, MBA, Cleveland Clinic, Organization, Risk, Safety, Survival, Disease, DSMB, Therapy, AAV, Cleveland, MYBPC3, Clinical trial, SAN, ClinicalTrials.gov, Relaxation, Human, HCM, Patient, Facial muscles, Pharmaceutical industry, Medical device

The working MYBPC3 gene is intended to restore normal levels of myosin-binding protein, which regulates the contraction and relaxation of the heart muscle.

Key Points: 
  • The working MYBPC3 gene is intended to restore normal levels of myosin-binding protein, which regulates the contraction and relaxation of the heart muscle.
  • The MyPeak-1 clinical trial will be conducted at up to twelve leading U.S. centers specializing in HCM care.
  • The first site that is actively recruiting patients is the Hypertrophic Cardiomyopathy Center at the Cleveland Clinic, Cleveland, Ohio.
  • To learn more about gene therapy for HCM and participation in the MyPeak-1 study, please visit HCMStudies.com or ClinicalTrials.gov (NCT05836259) .

Phase III studies to investigate survodutide for people living with obesity and overweight, with and without diabetes, cardiovascular disease and chronic kidney disease

Retrieved on: 
Thursday, October 5, 2023
Cardiovascular disease, III, BMI, Type 2 diabetes, European Association for the Study of Diabetes, Hypertension, Obesity, Prevalence, A1C, Disease, Overweight, Principal, Conditional sentence, EASD, Phase, Appetite, Dyslipidemia, Chronic kidney disease, Obstructive sleep apnea, BI, Zealand Pharma, Boehringer Ingelheim, University college, Risk, Pharmaceutical industry, Electric motor, Dietary supplement, Diabetes

Phase III studies to investigate survodutide for people living with obesity and overweight, with and without diabetes, cardiovascular disease and chronic kidney disease

Key Points: 
  • Phase III studies to investigate survodutide for people living with obesity and overweight, with and without diabetes, cardiovascular disease and chronic kidney disease
    SYNCHRONIZE-1 and SYNCHRONIZE-2 are global Phase III studies of survodutide (BI 456906) in people living with obesity and overweight without and with type 2 diabetes, respectively
    A third study, SYNCHRONIZE-CVOT, is a global, long-term cardiovascular safety study of survodutide in people living with obesity and overweight with cardiovascular disease, chronic kidney disease or with risk factors for cardiovascular disease
    Boehringer Ingelheim and Zealand Pharma A/S (NASDAQ: ZEAL) announced the initiation of three Phase III trials investigating survodutide (also known as BI 456906) for people living with overweight or obesity.
  • The trial design builds upon learnings from Phase II, in which people living with overweight or obesity achieved up to 19 percent weight loss.1 The Phase III trials will soon open for recruitment.
  • SYNCHRONIZE-1 will enrol people without type 2 diabetes (A1C
  • The third study, SYNCHRONIZE-CVOT, is a Phase III trial that will enrol people with overweight or obesity with cardiovascular disease, chronic kidney disease, or risk factors for cardiovascular disease.

10X Capital Venture Acquisition Corp. III Announces Transfer of Listed Securities to the NYSE American

Retrieved on: 
Wednesday, October 4, 2023
III, NYSE, Warrant, Bangladesh Securities and Exchange Commission, NYSE American, Security (finance), Unit

New York, NY, Oct. 04, 2023 (GLOBE NEWSWIRE) -- 10X Capital Venture Acquisition Corp. III (NYSE: VCXB.U, VCXB, VCXB WS) (“10X III”) today announced that it is transferring the listing of its Class A ordinary shares, par value $0.0001 per share (“Class A Ordinary Shares”), redeemable warrants, each exercisable to purchase one Class A Ordinary Share at a price of $11.50 per share (the “Warrants”), and units, each consisting of one Class A Ordinary Share and one-half of one Warrant (the “Units” and, together with the Class A Ordinary Shares and the Warrants, the “Listed Securities”), from the New York Stock Exchange (the “NYSE”) to the NYSE American LLC (the “NYSE American”).

Key Points: 
  • New York, NY, Oct. 04, 2023 (GLOBE NEWSWIRE) -- 10X Capital Venture Acquisition Corp. III (NYSE: VCXB.U, VCXB, VCXB WS) (“10X III”) today announced that it is transferring the listing of its Class A ordinary shares, par value $0.0001 per share (“Class A Ordinary Shares”), redeemable warrants, each exercisable to purchase one Class A Ordinary Share at a price of $11.50 per share (the “Warrants”), and units, each consisting of one Class A Ordinary Share and one-half of one Warrant (the “Units” and, together with the Class A Ordinary Shares and the Warrants, the “Listed Securities”), from the New York Stock Exchange (the “NYSE”) to the NYSE American LLC (the “NYSE American”).
  • 10X III’s decision to transfer to the NYSE American was motivated by several factors, including more favorable thresholds for continued listing on the NYSE American.
  • Following the transfer, 10X III intends to continue to file the same types of periodic reports and other information it currently files with the Securities and Exchange Commission (the “SEC”).
  • 10X III expects that the trading of its Listed Securities on the NYSE will end at market close on or about October 6, 2023 and that the trading of its Listed Securities on the NYSE American will commence at market open on or about October 9, 2023 under the current ticker symbols, VCXB, VCXB WS and VCXB.U for the Class A Ordinary Shares, Warrants and Units, respectively.

Cosmo announces submission of Winlevi® to the European Medicines Agency (EMA)

Retrieved on: 
Tuesday, October 17, 2023
III, European, Prescription, IQVIA, Cosmo, Ageing, Safety, Sun Pharma, EMA, FDA, Marketing Authorisation Application, European Medicines Agency, Marketing, IGA, Acne, XETRA, Dermatology, Patient, C43, MAA, Pharmaceutical industry, Medical device, EU

This filing marks a significant milestone in pipeline progression, as approval will open the substantial EU market to already selected, high-standing partners.

Key Points: 
  • This filing marks a significant milestone in pipeline progression, as approval will open the substantial EU market to already selected, high-standing partners.
  • Cosmo has officially submitted the Marketing Authorisation Application (MAA) for its innovative acne treatment clascoterone 1% cream (Winlevi®) to the European Medicine Agency (EMA) through the centralized procedure, aimed at obtaining a single Marketing Authorization for the product in the European Union.
  • The EMA's rigorous evaluation process will assess the product's safety, quality, and efficacy, ultimately determining its suitability for approval within the European market.
  • This submission to the EMA is a pivotal step forward in our mission as well as a testament to our ongoing commitment to innovation.

Ault Alliance Enters Agreement with Ault & Company to Restructure $17.5 Million of Liabilities into Long-Term Convertible Debt

Retrieved on: 
Monday, October 16, 2023
Professional Services, Blockchain, Technology, Cryptocurrency, Software, Finance, Fintech, III, Retirement, NYSE, Common, AAI, Conversion, Warrant, Common stock, Storey, Agreement, NYSE American, Exercise, Note, Security (finance), Sale

Ault Alliance, Inc. (NYSE American: AULT), a diversified holding company (“AAI,” or the “Company”), today announced that it has entered into a note purchase agreement (the “Agreement”) with Ault & Company, Inc., a related party (“A&C”).

Key Points: 
  • Ault Alliance, Inc. (NYSE American: AULT), a diversified holding company (“AAI,” or the “Company”), today announced that it has entered into a note purchase agreement (the “Agreement”) with Ault & Company, Inc., a related party (“A&C”).
  • The Note also has “full ratchet” price protection in the event the Company should issue securities at a lower price than the Conversion Price.
  • Despite various evolutions, name shifts, and acquisitions effectuated by AAI, AAI’s primary objective to foster a resilient holding company remains unchanged.
  • This debt restructuring reflects A&C’s ongoing dedication to enable AAI to meet its financial commitments and expand its business.

FDA Approves KEYTRUDA® (pembrolizumab) for Treatment of Patients With Resectable (T≥4 cm or N+) NSCLC in Combination With Chemotherapy as Neoadjuvant Treatment, Then Continued as a Single Agent as Adjuvant Treatment After Surgery

Retrieved on: 
Tuesday, October 17, 2023
Oncology, Health, FDA, Surgery, Clinical Trials, Pharmaceutical, Biotechnology, MSD, Congress, III, Hepatitis, HIV disease progression rates, Immunosuppression, MRK, NYSE, Lung cancer, Food, Platinum, American Joint Committee on Cancer, Pembrolizumab, The New England Journal of Medicine, AJCC, OS, PD-L1, Colitis, EGFR, Stanford University, Medicine, Pemetrexed, Patient, ESMO, Merck & Co., Steroid, EFS, II, Carboplatin, TPS, Pneumonitis, Paclitaxel, History, Head, International Association, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, European Society for Medical Oncology, Neoplasm, Hematopoietic stem cell transplantation, European Society of Gynaecological Oncology, T2A, ALK, Nephritis, Pharmaceutical industry, Vaccine, NSCLC, Merck

With this approval, KEYTRUDA has six indications in NSCLC, across both metastatic and earlier stages of NSCLC.

Key Points: 
  • With this approval, KEYTRUDA has six indications in NSCLC, across both metastatic and earlier stages of NSCLC.
  • The EFS results, which were from the first interim analysis, were published in June 2023 in the New England Journal of Medicine.
  • Adverse reactions occurring in patients with resectable NSCLC receiving KEYTRUDA in combination with platinum-containing chemotherapy, given as neoadjuvant treatment and continued as single agent adjuvant treatment, were generally similar to those occurring in patients across tumor types receiving KEYTRUDA in combination with chemotherapy.
  • Eighty-one percent of patients in the KEYTRUDA in combination with platinum-containing chemotherapy arm had definitive surgery compared to 76% of patients in the placebo in combination with platinum-containing chemotherapy arm.

Wills Group Announces Appointment of Mark Samuels as Executive Vice President of Convenience Retailing

Retrieved on: 
Wednesday, October 11, 2023
Retail, Convenience Store, Food, Beverage, Plata, III, Multimedia, Convenience, Wills, BISU Visual Identity, Blackie, Dash Dolls, Mid-Atlantic (United States), Photograph, Samuels, Marketing, Convenience Retail Asia, Convenience store, Management, Dash, Splash

The Wills Group, a family-owned company headquartered in La Plata, Maryland, announced today the appointment of Mark Samuels to Executive Vice President of Convenience Retailing , effective as of October 1, 2023.

Key Points: 
  • The Wills Group, a family-owned company headquartered in La Plata, Maryland, announced today the appointment of Mark Samuels to Executive Vice President of Convenience Retailing , effective as of October 1, 2023.
  • View the full release here: https://www.businesswire.com/news/home/20231011988926/en/
    Mark Samuels appointed Executive Vice President of Convenience Retailing at the Wills Group (Photo credit: Ana Isabel Martinez Chamorro).
  • (Blackie) Wills, III, President and CEO of the Wills Group.
  • “I am honored to take on this expanded leadership role at the Wills Group,” said Samuels, Executive Vice President of Convenience Retailing at the Wills Group.